ADMETRx Now

ADMETRx takes an active leadership role in its industry, and has a strong professional presence in the field of discovery and preclinical ADME research.

As frequent invited speakers to national and international meetings, the ADMETRx Co-Founders, Phil Burton and Jay Goodwin may be in your area in the near future. Below is a list of just a few of their upcoming engagements:

Client Visit to WA/British Columbia: WA/British Columbia; August 5-7, 2008; Details: Phil Burton will be visiting with clients in Washington and British Columbia on August 5-7, 2008. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at mwarren@admetrx.com.

Client visit to New Jersey/Pennsylvania: New Jersey/Pennsylvania; July 15-17, 2008; Details: Phil Burton will be visiting with clients in New Jersey and Pennsylvania, July 15-17. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at mwarren@admetrx.com.

Client visit to San Diego/San Francisco: California; June 18-20, 2008; Details: Phil Burton will be visiting with clients in San Diego & San Francisco, June 18 - 20. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at mwarren@admetrx.com.

Client visit to Boston: Massachusetts; June 2-3, 2008; Details: Phil Burton will be visiting with clients in RTP, May 8 - 9. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at mwarren@admetrx.com.

Client visit to North Carolina/RTP: North Carolina; May 8 - 9, 2008; Details: Phil Burton will be visiting with clients in RTP, May 8 - 9. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at mwarren@admetrx.com.

ADMETRx at SBS National Conference: St. Louis, MO; April 9, 2008; Details: Dr. Philip Burton, co-founder and CSO of ADMETRx, is conducting a seminar entitled “Challenges & Strategies in Making Effective Use of Early ADMET Data” that will be presented at the Society for Biomolecular Sciences on Wednesday, April 9 in St. Louis, Missouri.; For additional information and registration, go to:
www.sbsonline.org/sbscon/2008/index.php

CHI Molecular Medicine Tri-Conference: San Francisco, CA; March 25-28, 2008; Details: Phil Burton, CSO of ADMETRx, will be conducting two short courses, on “ADMET CASE STUDIES FROM A MEDICINAL CHEMISTRY PERSPECTIVE” and “MODELS FOR EVALUATING DRUG-DRUG INTERACTION POTENTIAL IN PRECLINICAL DEVELOPMENT”, at the CHI Molecular Medicine Tri-Conference in San Francisco, CA on Tuesday, March 25.; For additional information and registration, go to:
http://www.tri-conference.com

Client visit to Maryland: March 6 – 7, 2008; Details: Phil Burton will be visiting with clients in Maryland, March 6 – 7. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at dhowe@admetrx.com.

Client visit at RTP: February 11 – 13, 2008; Details: Phil Burton will be visiting with clients in RTP, February 11-13. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at dhowe@admetrx.com.

ADMETRx SAB member winner of 2008 Skolnik Award: November 2007; Details: Gerry Maggiora, ADMETRx SAB member and Professor of Pharmaceutical Sciences at The University of Arizona and its BIO5 Institute, is the winner of the 2008 Herman Skolnik Award, from the ACS Division of Chemical Information. Gerry is a well-known thought-leader in the fields of chemical information systems, chemical diversity and similarity, and multi-criteria decision-making methods applied to drug discovery. For more information, see: http://acscinf.org/docs/awards/skolnik/2008.htm. The 2007 Skolnik Award winner is Bob Pearlman, also an ADMETRx SAB member and the Coulter R. Sublett Regents Chair in Pharmacy at The University of Texas at Austin. Bob is the founder of Optive Research and developer of CONCORD, DiverseSolutions and many other widely-employed and highly-valued computational chemistry software packages.; For more information, see: http://acscinf.org/docs/awards/skolnik/2007.htm

Optimize Your Drug Candidate Advancement Decision-Making View ADMETRx poster sessions at the November 2007 AAPS meeting: November 11-15, 2007; Details: Phillip Burton, PhD, ADMETRx co-founder and CSO will be delivering two poster sessions at the AAPS annual meeting being held November 11-15, 2007 in San Diego, CA. The posters will both be presented on November 13th:; 8 a.m. – noon; A Model for Predicting CNS Penetration of Compounds from in vitro Membrane Permeability, P-glycoprotein Activity and Plasma Protein Binding Data (AM-07-02082); A novel multicriteria decision-making method for interrelating typical in vitro measurements to predict in vivo performance; 1 p.m. – 5 p.m.; Permeability Characteristics of Bilastine, a Potent and Selective H1 Receptor Antagonist, in Caco-2 Cells (AM-07-02910); A systematic approach for elucidating intestinal absorption mechanisms, using the Caco-2 cell model; Both poster sessions will focus on different preclinical research processes that optimize drug candidate advancement decision-making. View each in the Pharmaceutics and Drug Delivery Section in the San Diego Convention Center.

Client visit to Maryland: November 2, 2007; Details: Phil Burton will be visiting with clients in Maryland on November 2, 2007. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at dhowe@admetrx.com.

Drug Discovery & Development article: October 2007; Details: The fundamental role of in vitro, cell-based transport experiments in assessing potential drug-drug interactions (DDIs) is elaborated by Phil Burton in a recent Drug Discovery & Development article, 1. October 2007, “Warning!...Warning!”. Said Burton, “Since that (FDA) guidance (on transporter-based DDIs) was issued, we’ve just been flooded with requests to do transporter characterization, and this is just the beginning.”; For more information visit: http://www.dddmag.com/early-stage-ADME-tox-testing.aspx

Client visit to Boston: October 23-25, 2007; Details: Phil Burton will be visiting with clients in Boston, October 23-25, 2007. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at dhowe@admetrx.com.

Philip Burton, PhD explores the Implications of Drug Development Challenges in Genetic Engineering & Biotechnology News: September 2007; Details: In the September 2007 issue of Genetic Engineering & Biotechnology News) ADMETRx co-founder and CSO, Philip Burton, PhD explores the implications of the drug development challenges faced by the biotech and pharmaceutical industries. More important, he suggests some possible solutions that can assist industry members to identify winning candidates earlier and to advance only those that have demonstrable potential into clinical trials. “The challenge is not to advance more candidates but to advance the best of them”.; Contact dhowe@admetrx.com to receive a copy of this article.

Client visit to Southern and Northern California: August 20-22, 2007; Details: Phil Burton will be visiting with clients in Southern and Northern California, August 20 - 22. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at dhowe@admetrx.com.

Client visit at RTP: July 31, 2007; Details: Phil Burton will be visiting with clients in RTP, July 31. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at dhowe@admetrx.com.

Client visit to Boston: July 9-10, 2007; Details: Phil Burton Phil Burton will be visiting with clients in Boston, July 9-10. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at dhowe@admetrx.com.

Client visit to Southern and Northern California: June 12-14, 2007; Details: Phil Burton will be visiting with clients in Southern and Northern California, June 12-14. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at dhowe@admetrx.com.

Midwest Biopharmaceutical Statistics Workshop: Ball State University, Muncie, Indiana; May 21-23, 2007; Details: Phil Burton will be presenting on “Improving the Quality of Clinical Candidates: A Multi-Criteria Optimization Strategy” at the Midwest Biopharmaceutical Statistics Workshop Modeling the Relationship Between Clinical Outcome and Animal Models.; For more information visit: http://www.mbswonline.com

Client visit to New Jersey: May 16-18, 2007; Details: Phil Burton will be visiting with clients in New Jersey, May 16-18. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at dhowe@admetrx.com.

Drug Development: From Bench to Bedside Symposium: Fribourg, Switzerland; April 20, 2007; Details: Phil Burton will be presenting on “The Challenge of Multiparameter Optimization in Drug Design” at the Drug Development: From Bench to Bedside Symposium, sponsored by IIIe Cycle Romand en Sciences Biologiques; For more information visit: www.unifr.ch/biochem/B2B

Client visit at RTP: March 20-21, 2007; Details: Phil Burton will be visiting with clients in RTP, March 20-21. If you would be interested in meeting with Phil and learning more about ADMETRx, please contact us at 269.353.5541 or by email at dhowe@admetrx.com.

AAPS Workshop on Drug Transporters: Bethesda, MD; March 5-7, 2007; Details: Phil Burton will be presenting on “A Model for Predicting CNS Penetration from Membrane Permeability, P-glycoprotein Activity and Plasma Protein Binding in vitro Data” at the AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside.; For more information visit: http://www.aapspharmaceutica.com/meetings/meeting.asp?id=84

CHI Molecular Medicine Tri-Conference: San Francisco, CA; February 27, 2007; Details: Phil Burton, CSO of ADMETRx, will be conducting a short course on ”ADMET Case Studies from a Medicinal Chemistry Perspective” at the CHI Molecular Medicine Tri-Conference in San Francisco, CA on
February 27, 2007.; For additional information and registration, go to: http://www.tri-conference.com/sc.asp

Research Triangle Park: North Carolina; January 16-17, 2007; Details: Phil Burton, CSO, will be visiting several clients within the Research Triangle Park in NC on January 16th and 17th, 2007. If you are interested in meeting with Phil during this time, please contact Debi Howe (VP, Client Relations) at 269.353.5541 (dhowe@admetrx.com).

FibroGen, Inc.: 225 Gateway Blvd; South San Francisco, CA 94080; December 5, at 6:00 pm; Details: Phil Burton, CSO of ADMETRx, will be presenting at the San Francisco PK/PD Discussion group on December 5, at 6:00 pm.; Contact: Toufigh Gordi (tgordi@Depomedinc.com)

2006 AAPS Meeting: San Antonio, TX; October 29 - November 2, 2006; Details: Dr. Philip Burton, co-founder and CSO of ADMETRx, will be speaking at the 2006 AAPS Meeting in San Antonio. His presentation, “A Multi-Criteria Decision-making Strategy to Increase Effective Use of Discovery Data” will be on Tuesday, October 31 from 2:00-4:30. This presentation can be found under the “How to Select Optimal Approach to Improve the Delivery of Drug Development Candidates” section.; View Event Web Site

If you are interested in meeting individually with Dr. Burton, please contact us at 269-372-3272

The scientific staff at ADMETRx has published extensively. Dr. Burton has recently published a timely paper entitled “The challenge of improving the drug discovery process - An early ADME perspective.” To receive a copy of this paper as well as a complete list of publications, please contact us.